Zayıflama Amacıyla Kullanılan Çok Etken Maddeli Bazı Preparatların Toksikolojik Açıdan Değerlendirilmesi: Fen-Phen ve Usnik Asit

Yıl 2009, Sayı: 2, 131 - 148, 01.06.2009

Belma Giray Pınar Erkekoğlu Gönül Şahin

Öz

Kilo alımına karşı mücadelede 1940’lardan beri birçok ilaç ve bitkisel preparat kullanılmıştır. Bazıları ciddi yan etkilerinden dolayı kullanımdan kalkmıştır. Fen-Phen preparatları fenfluramin ve fentermin, usnik asit preparatları ise sodyum usniyat, fenilpropanolamin, yohimbin, kafein ve 3,5-diiyodotironin içermektedir. Fen-Phen preparatlarının kullanımı kardiyak valvulopatiye, usnik asit preparatlarının kullanımı ise ciddi karaciğer toksisitesine neden olmuştur. Ayrıca her iki tip ürünün kullanımıyla da ölümler görülmüştür. Her ne kadar fenfluramin artık kullanımından kalkmış olsa da, doktorlar halen fentermin ürünlerini reçetelendirmekte ve usnik asit preparatları ise internetten satın alınabilmektedir. Bu derlemede Fen-Phen ve usnik asit preparatlarının kullanımıyla ortaya çıkabilecek toksikolojik sonuçlar üzerinde durulacaktır.

Anahtar Kelimeler

Obezite, Zayıflama preparatları, Fen-Pen, Usnik asit

Toxicological Evaluation of Slimming Prepations with Several Ingredients

Öz

To aid the fighting against weight gain, many drugs or herbal preparations have been used since 1940s. Some of them are withdrawn from the market because of the serious side effects. Fen-Phen preparations contained fenfluramine and phentermine while usnic acid preparations had sodium usniate, phenylpropanolamine, yohimbine, caffeine and 3,5-diiodithyroinine as ingredients. Fen-Phen usage caused cardiac valvulopathy while preparations with usnic acid caused serious liver toxicity. Furthermore, there were several reports of deaths in patients taking these two kinds of preparations. Although fenfluramine is no longer available, physicians can still prescribe phentermine and preparations of usnic acid are still available on internet sales. This review will focus on Fen-Phen and usnic acid preparations and the possible toxicological outcomes in the usage of these two kinds of preparations.

Anahtar Kelimeler

Obesity, Slimming Products, Fen-Phen, Usnic acid

Kaynakça

• mokdad, A.H., Serdula, m.K., Dietz, W.H., Bowman, B.A., marks j.S., Koplan j.P. : The spread of the obesity epidemic in the united States, 1991-1998. jAmA, 282, 1519 (1999)
• Perharic, L., Shaw, D., murray, V. : Toxic effects of herbal medicines and food supple- ments, Lancet, 342, 180 (1993)
• Dunbabin D.W., Tallis G.A., Popplewell P.Y., Lee R.A. : Lead poisoning from Indian herbal medicine (Ayurveda), med j Aust, 157, 835, (1992)
• Kew, j., morris C., Aihie, A., Fysh, R, jones, S, Brooks, D. Arsenic and mercury intoxi- cation due to Indian ethnic remedies, Bmj, 306, 506, (1993)
• Slifman, N.R., obermeyer, W.R., Aloi, B.K., musser, S.m., Correll, W.A. jr, Cichowicz, S.m., Betz, j.m., Love, L.A. : Contamination of botanical dietary supplements by Digi- talis lanata, N Engl j med, 339, 806, (1998)
• Vessey, D., “metabolism of Xenobiotics”, Zakin B, (Ed). Hepatology: A Textbook of Liver Disease, 3rd ed, Philadelphia,: WB Saunders, (1996), sayfa 257.
• james, R.C., Harbison, R.D., Roberts, S.m. : Phenylpropanolamine potentiation of acetaminophen-induced hepatotoxicity: evidence for a glutathione-dependent mecha- nism, Toxicol Appl Pharmacol, 118, 159, (1993)
• Fishman, A,P. : Aminorex to fen/phen: an epidemic foretold, Circulation, 99, 156, (1999)
• Bray, G.A., Greenway, F.L. : Current and potential drugs for treatment of obesity, En- docr Rev, 20, 805, (1999)
• Coleman, E. : Anorectics on trial: A half century of federal regulation of prescriptions appetite suppressants, Ann. Intern med, 143, 380, (2005)
• Stafford, R.S., Radley, D.C. : National trends in antiobesity medication use, Arch Intern med, 163, 1046, (2003)
• Giri, m. : medical management of obesity, Acta Clin Belg, 61, 286, (2006)
• Bray, G.A. : Treatment and secondary prevention of obesity, Nutrition,16, 384, (2000)
• Dixon, j.B. : Weight loss medications--where do they fit in?, Aust Fam Physician, 35, 576, (2006)
• Bray, G.A. : Drug treatment of obesity, Rev Endocr metab Disord, 2, 403, (2001)
• Schnee, D.m., Zaiken, K., mcCloskey, W.W : Curr med Res opin, 22, 463, (2006)
• Ioannides-Demos, L.L., Proietto, j., Tonkin, A.m., mcNeil, j.j. : Safety of drug thera- pies used for weight loss and treatment of obesity. Drug Saf, 29, 277, (2006)
• Greenway FL, Caruso mK. : Safety of obesity drugs. Expert opin Drug Saf, 4, 1083, (2005)
• Li, Z., maglione, m., Tu, W., mojica, W., Arterburn, D., Shugarman, L.R., Hilton, L., Suttorp, m., Solomon, V., Shekelle, P.G., morton, S.C. : meta-analysis: pharmacologic treatment of obesity. Ann Intern med, 142, 532, (2005)
• Garrett, S.D., Cupp, m.j. : The fenfluramine/phentermine combination for weight loss. Nurse Pract, 22, 166, 1997.
• Fastin tablet. Drug Description. Available at: http://www.rxlist.com/fastin-drug.htm.
• Poston WS, 2nd, Foreyt jP, Borrell L, Haddock CK. Challenges in obesity management. South med j, 91, 710, (1998)
• Adipex-P. Drug Description. Available at: http://www.rxlist.com/adipex-p-drug.htm.
• Cannistra, L.B., Gaasch, W.H. : Appetite-suppressing drugs and valvular heart disease, Cardiol Rev,7, 356, (1999)
• Campbell, m.L., mathys, m.L.: Pharmacologic options for the treatment of obesity. Am j Health Syst Pharm, 58, 1301, (2001)
• Weissman, N.j., Panza, j.A, Tighe, j.F., Gwynne, j.T. : Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial, Ann Intern med, 134, 267, (2001)
• Spencer D.C., Hwang, j., morrell, m.j. : Fenfluramine-Phentermine (Fen-Phen) and Seizures: Evidence for an Association, Epilepsy Behav, 1, 448, (2000)
• Vaughan, S.F. : Fen-Phen-noumenon: A mass tort litigation and settlement about to come and go. Natl med Assoc, 94, C2, (2002)
• Fleming, R.m, Boyd, L.B. :The longitudinal effects of fenfluramine-phentermine use. Angiology, 58, 353, (2007)
• Connolly, H.m., Crary, j.L., mcGoon, m.D., Hensrud, D.D., Edwards, B.S., Edwards, W.D., Schaff, H.V. : Valvular heart disease associated with fenfluramine-phentermine. N Engl j med, 337, 581, (1997)
• Brown-Beasley, m.W. : After fen-phen/Redux: cardiac and pulmonary sequelae impli- cations for patient assessment. j Emerg Nurs. 24, 62, (1998)
• Weir E.K., Reeve, H.L., Huang, j.m., michelakis, E., Nelson, D.P., Hampl, V., Archer, S.L. : Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstric- tion. Circulation, 94, 2216, (1996)
• Simonneau, G., Galiè, N., Rubin, L.j., Langleben, D., Seeger, W., Domenighetti, G., Gibbs, S., Lebrec, D., Speich, R., Beghetti, m., Rich, S., Fishman, A. : Clinical classifi- cation of pulmonary hypertension. j Am Coll Cardiol, 43, 5S, (2004)
• Cohen, E. Study: diet pills yet another way to yo-yo. CNN Interactive, Health Story Page, November 26, 1996. Available at: http://www, cnn. corn~HEALTH~9611~26~nfm/in- dex.html.
• Favreau, j.T., Ryu, m.L., Braunstein, G., orshansky, G., Park, S.S., Coody, G.L., Love, L.A., Fong, T.L. : Severe hepatotoxicity associated with the dietary supplement LipoKi- netix, Ann Intern med, 136, 590, (2002)
• Dietary Supplement Warning. uS Department of Health and Human Services. uS Food and Drug Administration. FDA Consumer magazine, 2, 2, (2002)
• FDA Warns Consumers Not to use the Dietary Supplement LipoKinetix, Bethesda mD
• November 2001. Available at: http://www.cfsan.fda.gov/~dms/ds-lipo.html.
• Lipokinetix, Supplement used in Dieting, Blamed in or Death. News from obesity Week. 2, 1, (2002) Also Available online: http://www.obesityweek.org/members/Vol2/ News/020102.htm.
• Ingólfsdóttir, K. : usnic acid, Phytochemistry, 61, 729, (2002)
• Cocchietto, m., Skert, N., Nimis, P.L., Sava, G. : A review on usnic acid, an interesting natural compound, Naturwissenschaften, 89, 137, (2002)
• okuyama, E., umeyama, K., Yamazaki, m., Kinoshit,a Y., Yamamoto, Y. : usnic acid and diffractaic acid as analgesic and antipyretic components of usnea diffracta, Planta med, 61, 113, (1995)
• Shibata, S., ukita, T. : Relation between chemical constitutions and antibacterial ef- fects of usnic acid and its derivatives, jpn j med, 1, 152, (1948)
• Scirpa, P., Scambia, G., masciullo, V., Battaglia, F., Foti, E., Lopez, R., Villa, P., malecore, m., mancuso, S. : A zinc sulfate and usnic acid preparation used as post- surgical adjuvant therapy in genital lesions by Human Papillomavirus, minerva Gine- col, 51, 255, (1999)
• Takai, m., uehara, Y., Beisler, j.A. : usnic acid derivatives as potential antineoplastic agents, j med Chem, 22, 1380, (1979)
• Kristmundsdóttir, T., Aradóttir, H.A., Ingólfsdóttir, K., ogmundsdóttir, H.m. : Solubi- lization of the lichen metabolite (+)-usnic acid for testing in tissue culture, j Pharm Pharmacol, 54, 1447, (2002)
• Vijayakumar, C.S., Viswanathan, S., Reddy, m.K., Parvathavarthini, S., Kundu, A.B., Sukumar, E. : Anti-inflammatory activity of (+)-usnic acid, Fitoterapia, 71, 564, (2000)
• otsuka, H., Komiya, T., Tsukumi, m., Toyosato, T. and Fujimura, H. :　Studies on anti-inflammatory drugs. Anti-inflammatory activity of crude drugs and plants. (II).　j Takeda Res Lab, 31, 247, (1972)
• Abo-Khatwa, A.N., al-Robai, A.A., al-jawhari, D.A. : Lichen acids as uncouplers of oxi- dative phosphorylation of mouse-liver mitochondria, Nat Toxins, 4, 96, (1996)
• Guo, L., Shi, Q., Fang, j.L., mei, N., Ali, A.A., Lewis, S.m., Leakey, j.E., Frankos, V.H. : Review of usnic acid and usnea barbata toxicity, Environ Sci Health C Environ Car- cinog Ecotoxicol Rev, 26, 317, (2008)
• Lawrey j.D. : Biological role of lichen substances, Bryologist, 89, 111, (1986)
• Emmerich, R., Giez, I., Lange, o.L., Proksch, P. : Toxicity and antifeedant activity of lichen compounds against the polyphagous herbivorous insect Spodoptera littoralis. Phytoch, 33, 1389, (1993)
• Kingsbury. j.m., “Poisonous Plants of the united States and Canada” Kingsbury. j.m. (Ed), Prentice-Hall, Englewood Cliffs, Nj, (1964), sayfa 86.
• Soderberg, u. : A note on the action of usnic acid on anaesthetized cats, Acta Physiol Scand, 28, 202, (1953)
• NTP Nomination For usnic Acid and usnea Barbeta, 1, 8, (2005) Also Available at: http://ntp-server.niehs.nih.gov/ntp/htdocs/Chem_Background/ExSumPdf/usnic- Acid.pdf
• Koparal A.T., Tüylü, B.A., Türk, H. : In vitro cytotoxic activities of (+)-usnic acid and (-)-usnic acid on V79, A549, and human lymphocyte cells and their non-genotoxicity on human lymphocytes, Nat Prod Res, 20, 1300, (2006)
• al-Bekairi, A.m., Qureshi, S., Chaudhry, m.A., Krishna, D.R., Shah, A.H. : mitodepres- sive, clastogenic and biochemical effects of (+)-usnic acid in mice, j Ethnopharmacol, 33, 217, (1991)
• Correche, E.R, Carrasco, m., Escudero, m.E., Velaquez, L., Guzman, A.m.S., Giannini, F., Enriz, R.D., jauregui, E.A, Cenal, j.P., Giordano, o.S. : A study on the cytotoxic and antimicrobial activities of usnic acid and derivatives, Fitoterapia, 69, 493, (1998)
• Kumar, S., müler, K. : Lichen metabolites 2. Antiproliferative and cytotoxic- activity of gyrophoric, usnic and diffratic acid on human keratinocyte growth, j, Nat, Prod, 62
• Shibamoto, T., Wei, C.I. : mutagenicity of lichen constituents, Environ mutagen, 6, 757, (1984)
• De, F.L. : Don’t be so quick to ban medications, CmAj, 166, 13, (2002)
• Flavahan, N.A. Phenylpropanolamine constricts mouse and human blood vessels by preferentially activating alpha2-adrenoceptors, j Pharmacol Exp Ther, 313, 432, (2005)
• Clapp, R., Williams, m.L. : Regarding “phenylpropanolamine and hemorrhagic stroke in the hemorrhagic stroke project”., Ann Epidemiol, 16, 580, (2006)
• Lake, C.R., Gallant, S., masson, E., miller, P. : Adverse drug effects attributed to phen- ylpropanolamine: a review of 142 case reports, Am j med, 89, 195, (1990)
• Forman, H.P., Levin, S., Stewart, B., Patel, m., Feinstein, S. : Cerebral vasculitis and hemorrhage in an adolescent taking diet pills containing phenylpropanolamine: case report and review of literature, Pediatrics, 83, 737, (1989)
• Kernan, W.N., Viscoli, C.m., Brass, L.m., Broderick, j.P., Brott, T., Feldmann, E, mor- genstern, L.B., Wilterdink, j.L., Horwitz, R.I. : Phenylpropanolamine and the risk of hemorrhagic stroke, N Engl j med, 343, 1826, (2000)
• Balon, R. : Fluoxetine-induced sexual dysfunction and yohimbine, j Clin Psychiatry, 54, 161, (1993)
• Carey, m.P., johnson, B.T. : Effectiveness of yohimbine in the treatment of erectile disorder: four meta-analytic integrations, Arch Sex Behav, 25, 341, (1996)
• jacobsen, F.m. : Fluoxetine-induced sexual dysfunction and an open trial of yohimbine, j Clin Psychiatry, 53, 119, (1992)
• montague, D.K., Barada, j.H., Belker, A.m., Levine, L.A, Nadig, P.W., Roehrborn, C.G., Sharlip, I.D., Bennett, A.H. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction, The American urological As- sociation, j urol. 156, 2007, (1996)
• ostojic, S.m. Yohimbine: the effects on body composition and exercise performance in soccer players, . Res Sports med, 14, 289, (2006)
• Vogt, H.j., Brandl, P., Kockott, G., Schmitz, j.R., Wiegand, m.H., Schadrack, j., Gie- rend, m. : Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction, Int j Impot Res, 9, 155, (1997)
• Yohimbe Bark Extract. (Pausinystalia yohimbe Pierre ex Beille Rubiaceae) Avaialble at: http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-yohimbe.html. Last updated: February 01, 2008.
• mcCarty, m.F. : Pre-exercise administration of yohimbine may enhance the efficacy of exercise training as a fat loss strategy by boosting lipolysis, med Hypotheses, 58, 491, (2002)
• Gómez-Ambrosi, j., Frühbeck, G., Aguado, m., milagro, F.I., margareto, j., martínez, A.j. : Divergent effects of an alpha2-adrenergic antagonist on lipolysis and thermogen- esis: interactions with a beta3-adrenergic agonist in rats, Int j mol med, 8, 103, (2001)
• Galitzky, j., Lafontan, m., Nordenström, j., Arner, P. : Role of vascular alpha-2 adre- noceptors in regulating lipid mobilization from human adipose tissue, Clin Invest, 91, 1997, (1993)
• Kucio, C., jonderko, K., Piskorska, D. : Does yohimbine act as a slimming drug?, Isr j med Sci, 27, 550, (1991)
• Galitzky, j., Vermorel, m., Lafontan, m., montastruc, P., Berlan, m.: Thermogenic and lipolytic effect of yohimbine in the dog, Br j Pharmacol, 104, 514, (1991)
• Tam, S.W., Worcel, m., Wyllie, m. : Yohimbine: a clinical review, Pharmacol Ther, 291
• Shannon, m., Neuman, m.I. : Yohimbine, Pediatr Emerg Care, 16, 49, (2000)
• Yohimbe. Available at: http://nccam.nih.gov/health/yohimbe/ Newton, m.A., “Yohimbe bark” Blumenthal m, Goldberg A, Brinckman j, (Eds). Herbal medicine: Expanded Commission E monographs., Lippincott Williams & Wilkins, 2000, sayfa 429.
• Phyllis A. “Prescription for Nutritional Healing”, Balch, C (Ed). Fourth edition, CNC, Washington, (1998), sayfa 138.
• Fugh-Berman, A. : Herb-drug interactions, Lancet, 355, 134, (2000)
• moreno, m., de Lange, P., Lombardi, A., Silvestri, E., Lanni, A., Goglia, F. metabolic effects of thyroid hormone derivatives, Thyroid, 18, 239, (2008)
• Lanni, A., moreno, m., Lombardi, A., de Lange, P., Silvestri, E., Ragni, m., Farina, P., Baccari, G.C., Fallahi, P., Antonelli, A., Goglia, F. : 3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats, FASEB j, 19, 1552, (2005)
• Lombardi, A., de Lange, P., Silvestri, E., Busiello, R.A., Lanni, A, Goglia, F., moreno, m. : 3,5-Diiodo-L-thyronine rapidly enhances mitochondrial fatty acid oxidation rate and thermogenesis in rat skeletal muscle: AmP-activated protein kinase involvement, Am j Physiol Endocrinol metab, 296, E497, (2009)
• Wiersinga, W.m. L-T4 and L-T3 combined treatment vs L-T4 alone, Ann Endocrinol (Paris), 68, 216, (2007)
• Thyroid Problems. Hyperthyroidism. Available at: http://www.thyroidproblems.org/ hyperthyroidism.php.
• The Hormone Foundation. Thyroid Disorders Resources. Available at: http://www.hor- mone.org/thyroid/
• Newton, R., Broughton, L.j., Lind, m.j., morrison, P.j., Rogers, H.j., Bradbrook, I.D. Plasma and salivary pharmacokinetics of caffeine in man, Eur j Clin Pharmacol, 21, 45, (1981)
• Caffeine. Pharmacology and Interactions. Available at: http://www.pharmgkb.org/do/ serve?objId=PA448710&objCls=Drug#tabview=tab1.
• Pittler, m.H., Ernst, E. : Complementary therapies for reducing body weight: a system- atic review, Int j obes (Lond), 29, 1030, (2005)
• Greenway, F.L. : The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent, obes Rev, 2, 199 (2001)
• Broderick, P., Benjamin, A.B. : Caffeine and psychiatric symptoms: a review, j okla State med Assoc, 97, 538, (2004)
• Fisone, G., Borgkvist, A., usiello, A. : Caffeine as a psychomotor stimulant: mechanism of action, Cell mol Life Sci,61, 857, (2004)
• Graham, T.E., Rush, j.W., van Soeren, m.H. : Caffeine and exercise: metabolism and performance, Can j Appl Physiol, 19, 111, (1994)
• Fredholm, B.B., Bättig, K., Holmén, j., Nehlig, A., Zvartau, E.E. : Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Phar- macol Rev. 51, 83, (1999)
• Verkhratsky, A. : Physiology and pathophysiology of the calcium store in the endoplas- mic reticulum of neurons, Physiol Rev, 85, 201, (2005)
• Dews, P.B. : Comments on some major methodologic issues affecting analysis of the behavioral effects of foods and nutrients,. Psychiatr Res, 17, 223, (1982)
• Leson, C.L., mcGuigan, m.A., Bryson, S.m. : Caffeine overdose in an adolescent male, j Toxicol Clin Toxicol, 26, 407, (1988)
• Caffeine-Related Disorders. Available at: http://www.minddisorders.com/Br-Del/Caf- feine-related-disorders.html
• Corti, R., Flammer, A.j., Hollenberg, N.K., Lüscher, T.F. Cocoa and cardiovascular health, Circulation, 119, 1433, (2009)
• Caffeine Effects. Available at: http://www.erowid.org/chemicals/caffeine/caffeine_ef- fects.shtml.
• Caffeine. Available at: http://www.nlm.nih.gov/medlineplus/caffeine.html
• Hofbauer, K.G., Nicholson, j.R, Boss o. : The obesity epidemic: current and future pharmacological treatments. Ann Rev Pharmacol Toxicol. 47, 565, (2007)
• Süsleyici Duman, B., Kayhan, F.E., Sesal, C. obezite genetiği. Türkiye Klinikleri j med Sci, 29, 520, (2009)
• Saraçoğlu, A., Ergun, B. : Türkiye’de satılan bazı bitkisel zayıflama çaylarının içerikleri ve bu çayların kullanımına bağlı ortaya çıkabilecek istenmeyen etkiler. Türkiye Klinikleri j med Sci, 26, 355, (2006)
• Erkekoğlu, P., Giray, B., Şahin, G. : Türkiye’de zayıflama amacıyla kullanılan toz karışımların ve likit preparatların toksikolojik açıdan değerlendirilmesi. Hacettepe Tıp Dergisi, 40, 205, (2009)